| Cover - shares | 3 Months Ended | |
| Mar. 31, 2024 | May 13, 2024 | |
| Cover [Abstract] | ||
| Document Type | 10-Q | |
| Amendment Flag | false | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Document Period End Date | Mar. 31, 2024 | |
| Document Fiscal Period Focus | Q1 | |
| Document Fiscal Year Focus | 2024 | |
| Current Fiscal Year End Date | --12-31 | |
| Entity File Number | 001-13467 | |
| Entity Registrant Name | Inhibitor Therapeutics, Inc. | |
| Entity Central Index Key | 0001042418 | |
| Entity Tax Identification Number | 30-0793665 | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Address, Address Line One | 4905 South West Shore Blvd | |
| Entity Address, City or Town | Tampa | |
| Entity Address, State or Province | FL | |
| Entity Address, Postal Zip Code | 33611-3329 | |
| City Area Code | 813 | |
| Local Phone Number | 864-2562 | |
| Entity Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | false | |
| Entity Shell Company | false | |
| Entity Common Stock, Shares Outstanding | 172,323,545 |
| Condensed Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
| Current assets: | ||
| Cash and cash equivalents | $ 7,681,821 | $ 8,839,912 |
| Prepaid expenses and other assets | 112,399 | 109,243 |
| Total current assets | 7,794,220 | 8,949,155 |
| Total assets | 7,794,220 | 8,949,155 |
| Current liabilities: | ||
| Accounts payable | 111,916 | 33,731 |
| Accrued expenses and other liabilities | 43,934 | 631,433 |
| Total current liabilities | 155,850 | 665,164 |
| Deferred revenue | 3,000,000 | 3,000,000 |
| Total liabilities | 3,155,850 | 3,665,164 |
| Commitments and contingencies (Note 5) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 500,000,000 shares authorized; 172,323,545 and 172,023,545 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 17,232 | 17,202 |
| Additional paid-in capital | 54,085,905 | 54,046,845 |
| Accumulated deficit | (49,464,767) | (48,780,056) |
| Total stockholders’ equity | 4,638,370 | 5,283,991 |
| Total liabilities and stockholders’ equity | 7,794,220 | 8,949,155 |
| Series A Preferred Stock [Member] | ||
| Stockholders’ equity: | ||
| Preferred Stock, value | ||
| Series B Convertible Preferred Stock [Member] | ||
| Stockholders’ equity: | ||
| Preferred Stock, value | ||
| Undesignated Preferred Stock [Member] | ||
| Stockholders’ equity: | ||
| Preferred Stock, value |
| Condensed Balance Sheets (Parenthetical) - $ / shares | Mar. 31, 2024 | Dec. 31, 2023 |
| Common stock, par value | $ 0.0001 | $ 0.0001 |
| Common stock, shares authorized | 500,000,000 | 500,000,000 |
| Common stock, shares issued | 172,323,545 | 172,023,545 |
| Common stock, shares outstanding | 172,323,545 | 172,023,545 |
| Series A Preferred Stock [Member] | ||
| Preferred stock, par value | $ 0.0001 | $ 0.0001 |
| Preferred stock, shares authorized | 500,000 | 500,000 |
| Preferred stock, shares issued | 0 | 0 |
| Preferred stock, shares outstanding | 0 | 0 |
| Series B Convertible Preferred Stock [Member] | ||
| Preferred stock, par value | $ 0.0001 | $ 0.0001 |
| Preferred stock, shares authorized | 7,246,377 | 7,246,377 |
| Preferred stock, shares issued | 0 | 0 |
| Preferred stock, shares outstanding | 0 | 0 |
| Undesignated Preferred Stock [Member] | ||
| Preferred stock, par value | $ 0.0001 | $ 0.0001 |
| Preferred stock, shares authorized | 2,253,623 | 2,253,623 |
| Preferred stock, shares issued | 0 | 0 |
| Preferred stock, shares outstanding | 0 | 0 |
| Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
| Mar. 31, 2024 | Mar. 31, 2023 | |
| Income Statement [Abstract] | ||
| Revenues: | ||
| Expenses: | ||
| Research and development | 235,359 | 201,398 |
| General and administrative | 539,458 | 428,326 |
| Total expenses | 774,817 | 629,724 |
| Loss from operations | (774,817) | (629,724) |
| Other income: | ||
| Interest income | 90,106 | 90,128 |
| Net loss | $ (684,711) | $ (539,596) |
| Basic net loss per share | $ 0 | $ 0 |
| Diluted net loss per share | $ 0 | $ 0 |
| Weighted average common stock shares outstanding - basic | 172,079,589 | 171,793,134 |
| Weighted average common stock shares outstanding - diluted | 172,079,589 | 171,793,134 |
| Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) | Series B Convertible Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
| Beginning balance at Dec. 31, 2022 | $ 17,179 | $ 54,033,084 | $ (45,753,921) | $ 8,296,342 | |
| Beginning balance, shares at Dec. 31, 2022 | 171,793,134 | ||||
| Net loss | (539,596) | (539,596) | |||
| Ending balance at Mar. 31, 2023 | $ 17,179 | 54,033,084 | (46,293,517) | 7,756,746 | |
| Ending balance, shares at Mar. 31, 2023 | 171,793,134 | ||||
| Beginning balance at Dec. 31, 2023 | $ 17,202 | 54,046,845 | (48,780,056) | 5,283,991 | |
| Beginning balance, shares at Dec. 31, 2023 | 172,023,545 | ||||
| Issuance of common stock under equity incentive plan | $ 30 | 20,970 | 21,000 | ||
| Issuance of common stock under equity incentive plan, shares | 300,000 | ||||
| Stock-based compensation | 18,090 | 18,090 | |||
| Net loss | (684,711) | (684,711) | |||
| Ending balance at Mar. 31, 2024 | $ 17,232 | $ 54,085,905 | $ (49,464,767) | $ 4,638,370 | |
| Ending balance, shares at Mar. 31, 2024 | 172,323,545 |
| Condensed Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
| Mar. 31, 2024 | Mar. 31, 2023 | |
| Operating activities: | ||
| Net loss | $ (684,711) | $ (539,596) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 39,090 | |
| Changes in assets and liabilities: | ||
| Prepaid expenses | (3,156) | (28,348) |
| Accounts payable and other current liabilities | (509,314) | (189,339) |
| Net cash used in operating activities | (1,158,091) | (757,283) |
| Financing activities: | ||
| Payments made on notes payable | (411,000) | |
| Net cash used in financing activities | (411,000) | |
| Net change in cash and cash equivalents | (1,158,091) | (1,168,283) |
| Cash and cash equivalents at beginning of period | 8,839,912 | 11,951,224 |
| Cash and cash equivalents at end of period | $ 7,681,821 | $ 10,782,941 |
| Corporate Overview | 3 Months Ended |
| Mar. 31, 2024 | |
| Accounting Policies [Abstract] | |
| Corporate Overview | 1. Corporate Overview Overview Inhibitor Therapeutics, Inc., a Delaware corporation (the “Company”, “INTI”, “we”, “us” or similar terminology), is a pharmaceutical development company that is focused on developing and ultimately commercializing innovative therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. The Company also has explored and expects to continue to explore acquiring or licensing other innovative pre-clinical and clinical stage therapeutics addressing unmet needs for the treatment of cancer and other diseases based on repurposing active ingredients of already approved drugs. The accompanying unaudited condensed financial statements of the Company have been prepared without audit. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of March 31, 2024, and for all periods presented, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the Securities and Exchange Commission (“SEC”) rules and regulations. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2023, which are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the SEC on March 29, 2024 (the “2023 Annual Report”). The accompanying condensed balance sheet as of December 31, 2023 has been derived from the audited financial statements at that date but does not include all information and footnotes required by GAAP for complete financial statements. As used herein, the term “common stock” means the Company’s common stock, $ 0.0001 The results of operations for the three-month period ended March 31, 2024, are not necessarily indicative of results that may be expected for any other interim period or for the full fiscal year. Readers of this Quarterly Report are strongly encouraged to review the risk factors relating to the Company which are set forth in the 2023 Annual Report and the Company’s other filings with the SEC. Nature of the Business The Company’s current primary focus is on the development of therapies initially for basal cell carcinoma (“BCC”), prostate and lung cancers in the United States utilizing itraconazole, a drug currently approved by the U.S. Food and Drug Administration (“FDA”) to treat fungal infections, and which has an extensive history of safe and effective use in humans. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. On December 12, 2023, the Company entered into an Exclusive License Agreement (the “Agreement”) with Johns Hopkins University (“JHU”). Pursuant to the Agreement, JHU granted to the Company the exclusive worldwide patent rights to a Granted US Patent, No. 8,980,930 entitled “New Angiogenesis Inhibitors” (the “Patent”). The Patent relates to the treatment of prostate cancer, BCC including basal cell carcinoma nevus syndrome (“BCCNS”), and lung cancer. The Company has formally requested a Type-B, pre-investigational new drug application (“pre-IND”) meeting with the FDA to obtain feedback on the overall drug development and regulatory plan to use itraconazole for the treatment of BCC tumors in BCCNS patients, for which the Company has engaged the services of external experts in the field to assist with the process. INHIBITOR THERAPEUTICS, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2024 (Unaudited) |
| Liquidity and Management’s Plans | 3 Months Ended |
| Mar. 31, 2024 | |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
| Liquidity and Management’s Plans | 2. Liquidity and Management’s Plans The Company is presently focused on its business plan of developing and ultimately commercializing innovative therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery. The Company expects to progress with the FDA during 2024 to reach a conclusion on whether any additional clinical trials are required before submitting a New Drug Application (“NDA”). The current cash on hand, approximately $ 7.7 |
| Summary of Significant Accounting Policies | 3 Months Ended |
| Mar. 31, 2024 | |
| Accounting Policies [Abstract] | |
| Summary of Significant Accounting Policies | 3. Summary of Significant Accounting Policies Estimates The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Revenue Recognition The Company currently has no ongoing source of revenue. Miscellaneous income, including interest, is recognized when earned by the Company. Deferred revenue represents cash received for royalties in advance of being earned. Such payments are reflected as deferred revenue until recognized under the Company’s revenue recognition policy. Deferred revenue would be classified as current if management believes the Company will be able to recognize the deferred amount as revenue within twelve months of the balance sheet date. Deferred revenue will be recognized when the product is sold and the royalty is earned. Since all deferred revenue is related to the BCCNS product, which is yet to be approved by FDA, the Company has determined that 100 3.0 Cash and Cash Equivalents The Company considers all highly liquid debt instruments with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in bank accounts in excess of Federal Deposit Insurance Corporation insured amounts. The Company continues to monitor the third-party depository institutions that hold the Company’s cash and limits its cash deposits to financial institutions with high credit standing. Research and Development Expenses Research and development (“R&D”) costs are expensed in the period in which they are incurred and include salaries, benefits and other related costs to support the Company’s R&D operations, amounts paid to third parties who conduct research and development activities on behalf of the Company, as well as the costs of discovery research, preclinical and clinical development, drug formulation and licensing payments. Upfront and advanced licensing payments for future use in R&D activities are recorded as prepaid expenses and are expensed as the related services are performed. INHIBITOR THERAPEUTICS, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2024 (Unaudited) General and Administrative Expenses General and administrative (“G&A”) expenses are expensed in the period in which they are incurred and include operating expenses not classified as R&D expenses, such as salaries, benefits, insurance, board of directors fees, travel costs, as well as fees for professional services related to accounting, tax and legal matters. Penalties and interest assessed as a result of unresolved tax liabilities are also classified as G&A expenses. Stock-Based Compensation The Company accounts for stock-based awards to employees and non-employees using Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718 – Accounting for Share-Based Payments, which provides for the use of the fair value-based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. Fair values of restricted stock units issued are determined by the Company based predominantly on the trading price of the common stock on the date of grant. The fair value of each common stock option is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on historical volatility of a peer group’s common stock and other factors estimated over the expected term of the options. The expected term of the options granted is derived using the “simplified method” which computes the expected term as the average of the weighted-average vesting term and the contract term. The risk-free rate is based on the U.S. Treasury yield. Income Taxes Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the financial statements as of March 31, 2024. Recent accounting pronouncements Management has considered all recent accounting pronouncements issued, but not effective, and does not believe that any will have a material impact on the Company’s results of operations or financial position. INHIBITOR THERAPEUTICS, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023 (Unaudited) |
| Stockholders’ Equity | 3 Months Ended |
| Mar. 31, 2024 | |
| Equity [Abstract] | |
| Stockholders’ Equity | 4. Stockholders’ Equity Employee Stock Plans During the three months ended March 31, 2024, the Company granted 300,000 0.02 During the three months ended March 31, 2024, the Company issued 270,000 0.08 0.07 0.02 4.33 5 129.86 no As of March 31, 2024, there were 2,845,646 100 6.0 0.09 0.05 There was approximately $ 0.04 |
| Legal Proceedings | 3 Months Ended |
| Mar. 31, 2024 | |
| Commitments and Contingencies Disclosure [Abstract] | |
| Legal Proceedings | 5. Legal Proceedings The Company may from time to time become a party to various legal proceedings arising in the ordinary course of business. The Company is not currently the subject of any pending legal proceedings. |
| Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
| Mar. 31, 2024 | |
| Accounting Policies [Abstract] | |
| Estimates | Estimates The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. |
| Revenue Recognition | Revenue Recognition The Company currently has no ongoing source of revenue. Miscellaneous income, including interest, is recognized when earned by the Company. Deferred revenue represents cash received for royalties in advance of being earned. Such payments are reflected as deferred revenue until recognized under the Company’s revenue recognition policy. Deferred revenue would be classified as current if management believes the Company will be able to recognize the deferred amount as revenue within twelve months of the balance sheet date. Deferred revenue will be recognized when the product is sold and the royalty is earned. Since all deferred revenue is related to the BCCNS product, which is yet to be approved by FDA, the Company has determined that 100 3.0 |
| Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid debt instruments with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in bank accounts in excess of Federal Deposit Insurance Corporation insured amounts. The Company continues to monitor the third-party depository institutions that hold the Company’s cash and limits its cash deposits to financial institutions with high credit standing. |
| Research and Development Expenses | Research and Development Expenses Research and development (“R&D”) costs are expensed in the period in which they are incurred and include salaries, benefits and other related costs to support the Company’s R&D operations, amounts paid to third parties who conduct research and development activities on behalf of the Company, as well as the costs of discovery research, preclinical and clinical development, drug formulation and licensing payments. Upfront and advanced licensing payments for future use in R&D activities are recorded as prepaid expenses and are expensed as the related services are performed. INHIBITOR THERAPEUTICS, INC. NOTES TO CONDENSED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2024 (Unaudited) |
| General and Administrative Expenses | General and Administrative Expenses General and administrative (“G&A”) expenses are expensed in the period in which they are incurred and include operating expenses not classified as R&D expenses, such as salaries, benefits, insurance, board of directors fees, travel costs, as well as fees for professional services related to accounting, tax and legal matters. Penalties and interest assessed as a result of unresolved tax liabilities are also classified as G&A expenses. |
| Stock-Based Compensation | Stock-Based Compensation The Company accounts for stock-based awards to employees and non-employees using Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718 – Accounting for Share-Based Payments, which provides for the use of the fair value-based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. Fair values of restricted stock units issued are determined by the Company based predominantly on the trading price of the common stock on the date of grant. The fair value of each common stock option is estimated on the date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatility is based on historical volatility of a peer group’s common stock and other factors estimated over the expected term of the options. The expected term of the options granted is derived using the “simplified method” which computes the expected term as the average of the weighted-average vesting term and the contract term. The risk-free rate is based on the U.S. Treasury yield. |
| Income Taxes | Income Taxes Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the financial statements as of March 31, 2024. |
| Recent accounting pronouncements | Recent accounting pronouncements Management has considered all recent accounting pronouncements issued, but not effective, and does not believe that any will have a material impact on the Company’s results of operations or financial position. |
| Corporate Overview (Details Narrative) - $ / shares | Mar. 31, 2024 | Dec. 31, 2023 |
| Accounting Policies [Abstract] | ||
| Common stock, par value | $ 0.0001 | $ 0.0001 |
| Liquidity and Management’s Plans (Details Narrative) - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
| Cash and cash Equivalents | $ 7,681,821 | $ 8,839,912 |
| Summary of Significant Accounting Policies (Details Narrative) - Royalty [Member] - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
| Product Information [Line Items] | ||
| Deferred revenue | $ 3 | $ 3 |
| Mayne Pharma [Member] | ||
| Product Information [Line Items] | ||
| Ownership percentage | 100% |
| Stockholders’ Equity (Details Narrative) - USD ($) | 3 Months Ended | |
| Mar. 31, 2024 | Mar. 31, 2023 | |
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
| Grant date fair value | $ 20,000 | |
| Shares issued | 270,000 | |
| Exercise price per share | $ 0.08 | |
| Grant date fair value | $ 0.07 | |
| Risk free interest rate | 4.33% | |
| Expected term | 5 years | |
| Expected volatility | 129.86% | |
| Dividend yield | $ 0 | |
| Stock based compensation | $ 39,090 | |
| Equity Incentive Plan [Member] | ||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
| Issuance of common stock under equity incentive plan, shares | 300,000 | |
| Grant date fair value | $ 20,000 | |
| Number of outstanding common stock options | 2,845,646 | |
| Vesting rights, percentage | 100% | |
| Options, weighted average remaining contractual life | 6 years | |
| Options, weighted average exercise price per share | $ 0.09 | |
| Aggregate intrinsic value outstanding common stock options | $ 50,000 | |
